# Nicotinic Acid for the Treatment of Alzheimer's Disease

> **NCT06582706** · PHASE1,PHASE2 · RECRUITING · sponsor: **Indiana University** · enrollment: 30 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Placebo Comparator
- **DRUG:** Extended Release Niacin

## Key facts

- **NCT ID:** NCT06582706
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06582706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06582706, "Nicotinic Acid for the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06582706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*